戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 atients with a response continued to receive eltrombopag.
2 s, resulting in the early discontinuation of eltrombopag.
3  1-2 study of immunosuppressive therapy plus eltrombopag.
4  to splenectomy, rituximab, romiplostim, and eltrombopag.
5 atient assigned to receive placebo was given eltrombopag.
6 LT patients whose platelet count improved on eltrombopag.
7 all patients could receive up to 24 weeks of eltrombopag.
8 median of 13 months (range, 1-15 months) off eltrombopag.
9 ceiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, an
10 atment, with 45 patients assigned to receive eltrombopag (16 children aged 12-17 years, 19 aged 6-11
11 ar proportions had MDS (50 [51%] patients to eltrombopag, 22 (47%) patients to placebo) or AML (48 [4
12  Proportionately fewer patients who received eltrombopag (23 [37%] of 63 patients) had WHO grades 1-4
13 nts to placebo) or AML (48 [49%] patients to eltrombopag, 25 [53%] patients to placebo).
14 millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily fo
15 ive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or 75 mg daily) or placebo.
16 tment received standard care plus once-daily eltrombopag 50 mg (n=76) or placebo (n=38) for up to 6 w
17 cacy, safety, and tolerability of once daily eltrombopag 50 mg, and explored the efficacy of a dose i
18 ents were randomly assigned (2:1) to receive eltrombopag (50 mg to 300 mg) or placebo for at least 24
19 0 mg by mouth, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in 12 adults with newly d
20 rom weeks 5-12 were significantly lower with eltrombopag (54% [95% CI 43-64]) than with placebo (69%
21  avoided in 104 of 145 patients who received eltrombopag (72%) and in 28 of 147 who received placebo
22 ia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist
23   All 5 patients with a platelet response to Eltrombopag, a thrombopoietic agent, but none responding
24                             We asked whether eltrombopag, a thrombopoietic agent, would increase plat
25 nd colleagues examine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA),
26                            We tested whether eltrombopag, a thrombopoietin receptor agonist, might be
27                               The effects of eltrombopag, a thrombopoietin-receptor agonist, on plate
28 hat were suspected to be study drug-related (eltrombopag: acute kidney injury, arterial thrombosis, b
29   Orally available, TPO nonpeptide mimetics (eltrombopag, AKR-501) bind and activate the TPO receptor
30   In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, fo
31                                              Eltrombopag, an oral thrombopoietin receptor agonist, in
32              In part 1, 17 patients received eltrombopag and 11 patients completed treatment; four ex
33                  21 (33%) patients receiving eltrombopag and 16 (47%) patients receiving placebo died
34         63 patients were assigned to receive eltrombopag and 29 were assigned to receive placebo.
35  occurred in five (8%) patients who received eltrombopag and four (14%) who received placebo.
36 ts occurred in five (11%) patients receiving eltrombopag and four (19%) patients receiving placebo, a
37 sessment of long-term safety and efficacy of eltrombopag and its effect on survival (phase 2 part of
38 her was reported in ten (16%) patients given eltrombopag and nine (26%) patients given placebo.
39        No significant difference between the eltrombopag and placebo groups was observed in bleeding
40  of other adverse events were similar in the eltrombopag and placebo groups.
41 TION: No new safety concerns were noted with eltrombopag and the trial met the primary objective of a
42 adverse events (four [9%] patients receiving eltrombopag and two (10%) patients receiving placebo) we
43              No deaths in patients receiving eltrombopag and two deaths in patients receiving placebo
44  of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag
45             During part 1, patients received eltrombopag, and dose-escalation criteria for part 2 wer
46 mbopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of el
47        Platelet responses to romiplostim and eltrombopag are seen in a much greater percentage than i
48                  Two agents, romiplostim and eltrombopag, are now licensed and their place in the tre
49 lacebo (13 [42%] of 31 patients) than in the eltrombopag arm (eight [14%] of 59 patients; p=0.0025).
50 tem were observed in 6 patients who received eltrombopag, as compared with 1 who received placebo, re
51 ding phase, patients aged 6-17 years started eltrombopag at 25 mg once per day (12.5 mg for those wei
52                Twenty-five patients received eltrombopag at a dose of 50 mg, which could be increased
53 atment period in which all patients received eltrombopag at either the starting dose (if they were fo
54  than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14
55                                              Eltrombopag belongs to a new class of thrombopoietin-mim
56 let reactivity to TRAP only in responders to eltrombopag but not to levels above those in controls; w
57               25 (40%) patients who received eltrombopag compared with one (3%) patient who received
58                                  Response to eltrombopag compared with placebo was not affected by pr
59 weeks 1 to 6, 28 (62%) patients who received eltrombopag, compared with seven (32%) who received plac
60                      Our results showed that eltrombopag could be used to increase platelet counts an
61 han 80% of patients receiving 50 or 75 mg of eltrombopag daily had an increased platelet count.
62                               In conclusion, eltrombopag/dexamethasone is a feasible frontline therap
63  baseline platelet activation than controls, eltrombopag did not cause platelet activation or hyper-r
64    However, two patients assigned to receive eltrombopag did not receive the study drug and one was l
65                                              Eltrombopag doses up to 300 mg daily had an acceptable s
66                                              Eltrombopag (ELT) is a thrombopoietin receptor agonist r
67                                              Eltrombopag (EP) is a small-molecule, nonpeptide thrombo
68 m analysis of the ongoing open-label EXTEND (Eltrombopag eXTENded Dosing) study evaluates the safety
69 ed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocyto
70         This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing
71 med to assess the safety and tolerability of eltrombopag for the treatment of thrombocytopenia in adu
72 preclinical rationale for further testing of Eltrombopag for treatment of thrombocytopenia in AML and
73 f the eltrombopag regimen (cohort 1 received eltrombopag from day 14 to 6 months, cohort 2 from day 1
74 ations were done in 40 (63%) patients in the eltrombopag group and 17 (50%) patients in the placebo g
75                     63 (98%) patients in the eltrombopag group and 32 (94%) patients in the placebo g
76                           73 patients in the eltrombopag group and 37 in the placebo group were inclu
77 er were reported in six (9%) patients in the eltrombopag group and four (12%) patients in the placebo
78 adverse events were fatigue (six [6%] in the eltrombopag group and one [2%] in the placebo group), hy
79 ccurred in seven (12%) of 59 patients in the eltrombopag group versus five (16%) of 31 patients in th
80 s occurred in 27 (46%) of 59 patients in the eltrombopag group versus nine events in five (16%) of 31
81 s occurred in 28 (47%) of 59 patients in the eltrombopag group versus one (3%) of 31 patients in the
82 cause of adverse events: two patients in the eltrombopag group withdrew because of increased liver am
83                                       In the eltrombopag groups receiving 30, 50, and 75 mg per day,
84 verse events were similar in the placebo and eltrombopag groups.
85                           Patients receiving eltrombopag had less bleeding at any time during the stu
86          The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and ef
87 t production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet count but
88         We have previously demonstrated that eltrombopag has efficacy in this setting with 44% (11/25
89                                              Eltrombopag has shown promising results in the treatment
90  thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of throm
91                          Among responders to eltrombopag, immature platelet fraction in 3 WAS/XLT pat
92 ) study evaluates the safety and efficacy of eltrombopag in 299 patients treated up to 3 years.
93 y evaluated long-term safety and efficacy of eltrombopag in adults with ITP who had completed a previ
94     The majority of patients who remained on eltrombopag in an extension study (14/17) continued to s
95 ed to investigate the efficacy and safety of eltrombopag in children with persistent or chronic immun
96 ined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe
97 th alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA.
98 aused two (3%) of 65 patients to discontinue eltrombopag in the open-label phase.
99                                  The role of eltrombopag in these patients warrants further investiga
100 placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrom
101 , developed new cytogenetic abnormalities on eltrombopag, including 5 with chromosome 7 loss or parti
102 rombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependen
103                                              Eltrombopag increased platelet counts in a dose-dependen
104                                              Eltrombopag increases and maintains hemostatic platelet
105  microthrombocytopenia; and (2) although the eltrombopag-induced increase in platelet production in W
106                                              Eltrombopag is a new, orally active thrombopoietin-recep
107             These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demo
108                                              Eltrombopag is a small molecule thrombopoietin receptor
109                                              Eltrombopag is a TPO nonpeptide mimetic administered ora
110                                              Eltrombopag is an effective treatment for managment of t
111                                              Eltrombopag is an oral thrombopoietin-receptor agonist.
112                                              Eltrombopag is an oral, non-peptide, thrombopoietin-rece
113     The oral thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chr
114                                              Eltrombopag is efficacious in a subset of patients with
115                              INTERPRETATION: Eltrombopag is well-tolerated in patients with lower-ris
116                                              Eltrombopag led to a slight increase in platelet reactiv
117                                  AMG 531 and eltrombopag markedly increase platelet counts in patient
118 e primary objective of a reduction in CRTEs; eltrombopag might be a treatment option for thrombocytop
119 domly assigned 98 patients to receive either eltrombopag (n=64) or placebo (n=34).
120 145 patients to receive supportive care plus eltrombopag (n=98) or placebo (n=47); similar proportion
121                                              Eltrombopag neither led to increased 5-bromo-2-deoxyurid
122      In this work, we studied the effects of Eltrombopag on proliferation, apoptosis, differentiation
123 (block size of three), to receive once-daily eltrombopag or matching placebo dose adjusted from 50 mg
124 ed supportive standard of care and initiated eltrombopag or placebo at 100 mg per day (50 mg per day
125 ould then be initiated, with continuation of eltrombopag or placebo for 12 additional weeks.
126 nd randomly assigned (2:1) to receive either eltrombopag or placebo tablets (or oral suspension formu
127  of eltrombopag) while the administration of eltrombopag or placebo was continued.
128 sing an interactive voice-response system to eltrombopag or placebo, stratified by baseline platelet
129 ntiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and
130 er L were randomly assigned (2:1) to receive eltrombopag or placebo.
131 ag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P<0.001).
132                                     43 (59%) eltrombopag patients and six (16%) placebo patients resp
133 nts were randomly assigned in a 2:1 ratio of eltrombopag:placebo by a validated randomisation system.
134 mine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improve blood counts.
135 sed clonogenic capacity at concentrations of Eltrombopag ranging from 0.1 to 30 microg/mL.
136                  Patients who were allocated eltrombopag received tablets (except for those aged 1-5
137                                          Two eltrombopag recipients (arterial thrombosis n=1; myocard
138                                        Seven eltrombopag recipients and two placebo recipients had se
139                                              Eltrombopag reduced the need for platelet transfusions i
140 timing of initiation and the duration of the eltrombopag regimen (cohort 1 received eltrombopag from
141 atients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the
142            Thrombopoietin receptor agonists (eltrombopag; romiplostim) seem to improve hemostasis, bu
143                                              Eltrombopag (SB-497 115) is a first-in-class, oral, smal
144 adults with ITP who had completed a previous eltrombopag study.
145 fficacy analysis who increased their dose of eltrombopag, ten (29%) responded.
146 se events that occurred more frequently with eltrombopag than with placebo included nasopharyngitis (
147                                              Eltrombopag therapy increases platelet counts in patient
148 rse events leading to study discontinuation (eltrombopag, three [4%]; placebo, two [5%]), were simila
149                              The addition of eltrombopag to immunosuppressive therapy was associated
150 ous adverse events were reported in 56 (58%) eltrombopag-treated patients and 32 (68%) placebo-treate
151 e platelet function in 20 patients receiving eltrombopag treatment at days 0, 7, and 28.
152                         In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients wi
153                                              Eltrombopag treatment resulted in an increased platelet
154 n response to high-dose ADP was lower during eltrombopag treatment than at baseline.
155 he 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years (2 days-8.76 years)
156                                       Before eltrombopag treatment with no ex vivo agonist, platelet
157 ithout added agonist was unchanged following eltrombopag treatment, whereas a slight increase in P-se
158 f grade 3-4 adverse events during treatment (eltrombopag, two [3%]; placebo, one [3%]) and adverse ev
159 g were headache (13 [30%] patients receiving eltrombopag vs nine [43%] patients receiving placebo), u
160       Responses were similar in all cohorts (eltrombopag vs placebo: 39% vs 10% for patients aged 12-
161 re similar (three [5%] patients who received eltrombopag vs two [7%] patients who received placebo).
162  clinical trial in 73 healthy male subjects, eltrombopag was administered as once-daily oral capsules
163                               Treatment with eltrombopag was associated with multilineage clinical re
164                   Furthermore, we found that Eltrombopag was capable of increasing megakaryocytic dif
165    EXTEND demonstrated that long-term use of eltrombopag was effective in maintaining platelet counts
166                     Long-term treatment with eltrombopag was generally safe, well tolerated, and effe
167 or the groups receiving 30, 50, and 75 mg of eltrombopag were 26,000, 128,000, and 183,000 per cubic
168                      The pharmacokinetics of eltrombopag were dose dependent and linear, and eltrombo
169          The most common adverse events with eltrombopag were headache (13 [30%] patients receiving e
170                                              Eltrombopag, which produced a sustained platelet respons
171 eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) while the administration of eltrombopag or

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top